Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) has announced that its proprietary MEAI-based binge behavior regulator program has received patent approval from the Macau International Intellectual Property Office, a special administrative region of China.
The company reports that the allowed patent pertains to, among other uses, primary amine aminoindan compound for regulating binge behavior. This includes compounds beyond 5-methoxy-2-aminoindan (MEAI), the company’s innovative psychedelic molecule.
In a statement, Dr. Adi Zuloff-Shani, CEO of Clearmind, said, “The issuance of this patent supports Clearmind’s efforts to establish a proprietary and differentiated IP portfolio in the psychedelic space with non-hallucinogenic proprietary molecules that have the potential to change the life of millions that struggle with substance addictions relating to alcohol and food.”
“We believe that our unique IP portfolio aligns with our mission to develop transformative treatments that address the underlying mechanisms of binge behaviors, helping individuals regain control over their lives,” Dr. Zuloff-Shani added.
